Researchers evaluated the effects of teriparatide among patients with rheumatoid arthritis and investigated the clinical determinants associated with increases in predicted bone strength and BMD.
Genetically predicted body mass index (BMI) significantly increases the risk of rheumatoid arthritis.
For patients with RA receiving DMARD therapy, continued use of glucocorticoids is associated with an increased risk for hospitalized infections.
DMARD therapy for rheumatoid arthritis (RA) treatment also cuts cardiovascular disease risk.
Researchers assessed the safety of hydroxychloroquine alone and in combination with azithromycin to determine the risk associated with its use in routine care in rheumatoid arthritis.
Researchers investigated the incidence rates of interstitial lung disease in patients with rheumatoid arthritis receiving tofacitinib and identified potential risk factors.
Researchers evaluated the prevalence of abdominal aortic calcification and its association with prevalent vertebral fractures in women with rheumatoid arthritis.
Researchers evaluated the short-term clinical efficacy of romosozumab in patients with rheumatoid arthritis and primary osteoporosis.
Researchers assessed the association between concomitant use of oral glucocorticoids and proton pump inhibitors and osteoporotic fracture risk in rheumatoid arthritis.
Researchers described the prevalence of self-reported frailty among patients with rheumatic musculoskeletal diseases and its associated factors.
